Key Points
- Luke Evnin, a director at Werewolf Therapeutics, sold 58,980 shares on Jan. 12 at an average of $0.57 for about $33,618 and executed multiple additional sales between Dec. 26 and Jan. 9.
- After these transactions his stake fell by 2.49% to 2,309,869 shares (valued at roughly $1.32M), and the trades were disclosed in an SEC Form 4.
- HOWL is trading near $0.57 (close to its 1‑year low of $0.56), has a market capitalization of about $27.9M, negative earnings, and an average analyst rating of "Hold" with a $3.75 price target.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 24,678 shares of the business's stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $0.61, for a total transaction of $15,053.58. Following the completion of the sale, the director directly owned 2,368,849 shares of the company's stock, valued at $1,444,997.89. The trade was a 1.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Luke Evnin also recently made the following trade(s):
- On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.57, for a total value of $33,618.60.
- On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $4,861.08.
- On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $7,625.60.
- On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total value of $26,494.65.
- On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $11,761.92.
- On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $11,697.84.
- On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.62, for a total value of $15,476.44.
- On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total transaction of $21,256.67.
- On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total transaction of $66,249.66.
- On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $22,448.16.
Werewolf Therapeutics Price Performance
HOWL opened at $0.57 on Tuesday. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The company's 50-day moving average price is $0.88 and its 200 day moving average price is $1.24. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.56 and a fifty-two week high of $2.38. The firm has a market cap of $27.89 million, a price-to-earnings ratio of -0.35 and a beta of 0.77.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last posted its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.03. As a group, sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.
Hedge Funds Weigh In On Werewolf Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in HOWL. Quadrature Capital Ltd purchased a new position in shares of Werewolf Therapeutics during the second quarter valued at $28,000. Qube Research & Technologies Ltd acquired a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at about $48,000. AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics in the first quarter worth approximately $79,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Werewolf Therapeutics in the second quarter worth approximately $92,000. Finally, Susquehanna International Group LLP boosted its holdings in shares of Werewolf Therapeutics by 16.9% during the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company's stock worth $183,000 after purchasing an additional 13,439 shares during the period. 64.84% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on HOWL shares. Wedbush lowered Werewolf Therapeutics from an "outperform" rating to a "neutral" rating and set a $1.00 target price on the stock. in a research report on Friday, December 19th. Weiss Ratings restated a "sell (d-)" rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Zacks Research cut shares of Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, November 21st. Bank of America cut their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a "buy" rating on the stock in a research report on Tuesday, November 18th. Finally, HC Wainwright decreased their target price on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a "buy" rating for the company in a research report on Friday, December 19th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $3.75.
Get Our Latest Stock Report on HOWL
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
